Blog Posts
Naveen Pemmaraju: New Research Highlights the CLIA Regimen for R/R AML
Naveen Pemmaraju/ youtube.com, Hannah Goulart/ X and Tapan Kadia/ faculty.mdanderson.org

Naveen Pemmaraju: New Research Highlights the CLIA Regimen for R/R AML

Naveen Pemmaraju, Professor in the Department of Leukemia at UT MD Anderson Cancer Center, shared on X:

“Highlighting the Cladribine – based approach for treatment of Patients with AML championed by Prof. Tapan Kadia and our team – great job Dr. Hannah Goulart leading this paper on CLIA program for patients with R/R AML.”

Title: Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial

Authors: Hannah Goulart, Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Elias Jabbour, Naveen Pemmaraju, Yesid Alvarado, Himachandana Atluri, Musa Yilmaz, Fadi G. Haddad, Kayleigh R. Marx, Caitlin Rausch, Sanam Loghavi, Nitin Jain, Guillermo Garcia-Manero, Farhad Ravandi-Kashani, Tapan M. Kadia

Read the full article.

You can also read:

Hairy Cell Leukemia in 2026: What’s New in Clinical Management?

Naveen Pemmaraju: New Research Highlights the CLIA Regimen for R/R AML

Acute Myeloid Leukemia AML Caitlin Rausch cancer Courtney D. DiNardo Elias Jabbour Fadi G. Haddad Farhad Ravandi-Kashani Gautam Borthakur Guillermo Garcia-Manero Hagop Kantarjian Hannah Goulart Himachandana Atluri Kayleigh R. Marx Musa Yilmaz Naval Daver Naveen Pemmaraju Nitin Jain OncoDaily Oncology Sanam Loghavi Tapan Kadia Tapan M. Kadia Yesid Alvarado